Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 26, 2015 5:35 AM ET


Company Overview of DNAtriX, Inc.

Company Overview

DNAtriX, Inc., a biotechnology company, engages in the development of an oncoloytic virus platform for the treatment of malignant glioma. The company’s product includes delta24RGD, an oncolytic adenovirus. DNAtriX is based in Houston, Texas.

One Greenway Plaza

Suite 930

Houston, TX 77046

United States

Key Executives for DNAtriX, Inc.

Chief Executive Officer and Director
Compensation as of Fiscal Year 2015.

DNAtriX, Inc. Key Developments

Merck & Company Collaborates with DNAtrix to Study DNX-2401, Keytruda in Glioblastoma

Merck & Company has entered into a collaboration with DNAtrix for an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix's oncolytic immunotherapy in combination with Keytruda. The phase 2 study will be on patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure.

DNAtriX, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 02:20 PM

DNAtriX, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 02:20 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Frank Tufaro, Chief Executive Officer and Director.

FDA Grants Orphan Drug Designation to DNAtrix, Inc.'s DNX-2401 for the Treatment Of Malignant Glioma

DNAtrix, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for DNX-2401, a conditionally-replicative oncolytic adenovirus for malignant glioma. Glioma is the most common form of primary brain cancer, the treatment of which remains a significant unmet medical need. Under the designation, companies are provided with development and commercial incentives for designated compounds. The company's DNX-2401 program has already been granted fast track status. The FDA's orphan drug program designates a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. It can be easier to gain marketing approval for drugs with orphan status, and orphan drugs typically also enjoy extended marketing exclusivity periods. Oncolytic virus therapy is based on the concept of using live viruses to selectively infect and replicate in cancer cells, with minimal destruction of normal tissue. Virus replication amplifies the input dose of the oncolytic virus and helps spread the agent to adjacent tumor cells. Moreover, there is evidence for a long-lasting anti-glioma immune effect that can lead to durable tumor destruction and long-term survival in some patients. DNX-2401, which has been engineered to be highly potent and selective for killing tumors, is currently being evaluated in clinical studies in the United States and Europe.

Similar Private Companies By Industry

Company Name Region
Delpor, Inc. United States
LiRIS Biomedical, Inc. United States
Gem Pharmaceuticals, LLC United States
Nebraska Cultures, Inc. United States
Global Biodiagnostics Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DNAtriX, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at